The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published in Gastroenterology. This ...
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy ...
June 15 (Reuters) - Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly ...
Zeposia is the first oral sphingosine-1-phosphate (S1P) receptor modulator to demonstrate benefit in moderate to severe ulcerative colitis in a Phase 3 study PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol ...
AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
ulcerative colitis, inflammatory bowel disease, IBD, UC Researchers performed a systematic review of clinical trials to assess the need for a consensus on the definition of mild to moderate, active ...
Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, led to clinically meaningful improvements in patients with moderately to severely active ulcerative colitis ...
Please provide your email address to receive an email when new articles are posted on . Zeposia (Ozanimod, Bristol Myers Squibb), the first sphingosine 1-phosphate (S1P) receptor modulator approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results